Compare Adaptive Biotechnologies Corp (ADPT) vs Manchester United PLC (MANU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Manchester United PLC — how do they compare? Adaptive Biotechnologies Corp trades at $25.03 (market cap $4.04B), while Manchester United PLC trades at $22.81 (market cap $3.80B). The key difference: Adaptive Biotechnologies Corp and Manchester United PLC are close in size by market cap, and Manchester United PLC pays a 1.26% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | MANU | |
|---|---|---|
Market Cap | $4.04B | $3.80B |
Sector | Health | Media |
52-Week High | $25.45 | $23.53 |
52-Week Low | $12.30 | $15.10 |
Enterprise Value | $4.10B | $4.74B |
Dividend Yield | — | 1.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $24.94, down 2.0% today but near its 52-week high. The stock shows a bullish technical trend with improving fundamentals, including 49% MRD revenue growth and narrowing losses. A recent 4:1 reverse stock split and planned business separation aim to unlock value, with analyst consensus leaning bullish.
Outlook is cautiously optimistic due to strong revenue growth and margin expansion, but risks persist from ongoing net losses and competitive pressures. The stock offers potential upside to the $25.50 consensus target if execution continues improving, yet volatility may remain until profitability is achieved.
Manchester United (MANU) trades at $22.60, up 4.15% today, with a bearish technical signal. The company reported Q1 2026 EPS of $0.04, beating expectations, but missed in Q4 2025. Revenue trends show modest growth to $667M in 2025, though net income remains negative. Key developments include securing land for a new stadium and Champions League qualification boosting future revenue prospects.
The outlook is mixed; stadium development and cost reductions offer long-term upside, but persistent losses and high debt pose risks. Analysts are cautious with 40% buy ratings. Investment opportunity hinges on operational turnaround, while risks include weak cash flow and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Manchester United PLC
Manchester United PLC operates a professional football club together with related and ancillary activities. The company manages the soccer team and all affiliated club activities of the Manchester United Football Club, which includes the media network, foundation, fan zone, news, sports features, and team merchandise. Manchester United is based in England. The company has three principal sectors from which most of the revenue is generated, including Commercial, Broadcasting, and Matchday.
Read more on MANU →
